Eugene、ORにおける非小細胞肺癌の臨床試験
Eugeneとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する13件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
被験者募集中第3相
- Oncology Associates Of Oregon, Pc, Eugene
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
被験者募集中第3相
- Oncology Associates of Oregon PC, Eugene
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Oncology Associates of Oregon, P.C., Eugene
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Oncology Associates of Oregon PC Willamette Valley Cancer Institute, Eugene
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
被験者募集中第1/2相
- Oncology Associates of Oregon, P.C., Eugene
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Site, Eugene
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
被験者募集中第2/3相
- USOR - Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- USO - Oncology Associates of Oregon, Eugene
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
被験者募集中第1相
- USOR - Oncology Associates of Oregon, P.C, Eugene
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
被験者募集中第2相
- Williamette Valley Cancer Institute and Research Center, Eugene
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- USOR Oncology Associates of Oregon, P.C., Eugene
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
被験者募集中第1相
- Willamette Valley Cancer Institute and Research Center, Eugene
MYLUNG Consortium Part 3: Observational Study
被験者募集中観察研究
- Willamette Valley Cancer Institute and Research Center, Eugene
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY120件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH56件の研究
- Washington, DC55件の研究
Eugeneにおける他の研究
- 卵巣がん9件の研究
- 子宮内膜がん8件の研究
- 乳がん7件の研究
- 慢性リンパ性白血病6件の研究
- 多発性骨髄腫6件の研究
- 転移性癌6件の研究
- がん（全種類）6件の研究
- 薬物使用と依存症5件の研究
- 肺がん5件の研究
- 黄斑変性症5件の研究
- 肥満症4件の研究
- 前立腺がん3件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。